Dean Schorno, former CFO of sequencing company Adaptive Technologies Corp, joins 23andMe amid plans to relaunch health-focused products. 

Genetic testing company 23andMe has carved out a substantial niche in the ancestry market, enabling consumers to get a look at their genome for the price of a $99 testing kit. Earlier this year they gained regulatory approval for a health-testing kit for Bloom syndrome, a condition associated with short stature and increased cancer risk, bringing to and end a tense stand-off with the US Food and Drug Administration. Amid plans to relaunch the kit at the end of the year, 23andMe yesterday announced that it has hired genetic-sequencing veteran Dean Schorno as CFO and head of operations. 

Schorno has previously worked as CFO for Adaptive Biotechnologies Corp, and before that at Genomic Health Inc. in various executive roles. “Leveraging the human genome is what I’ve been thinking about for much of my career,” Schorno said in an interview. Andy Page, president of 23andMe said that “Dean Schorno is a world class financial executive with deep operational and category experience who will bring discipline to the complexities of our business.”

The return of the heath test is expected to feed consumer data into 23andMe’s research partnerships and in particular its newly-formed therapeutics group, which is seeking to apply the company’s formidable genetic database to developing its own drugs. So far 80% of the 1 million people that 23andMe has run tests for have consented to have their anonymous data used in research.